ACST Acasti Pharma Inc.: צמיחה צפויה ברווח למניה לשנה הבאה

Acasti Pharma (ACST) is finalizing the Phase 3 data for its drug ONP-002 designed to combat hemorrhages. The forward earnings per share growth forecast demonstrates the trend of expectations, where the 31.90 level reflects the current magnitude. Protection against dumping is ensured by the FDA orphan drug status. Market capitalization relies on the supply of specialized agents to pharmacy chains and hospital centers.

The expected net income growth rate for the coming year measures aggregated market forecasts regarding the business's future ability to generate revenue. This forecast for next year's earnings per share on the GURU.Markets platform serves as a stress-testing tool, confirming the resilience of Acasti Pharma (ACST) to macroeconomic shocks due to the non-cyclical nature of drug development for rare pathologies and its reliance on internal liquidity reserves.